Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

APX005M and Doxorubicin in Treating Patients with Advanced Soft Tissue Sarcoma

Trial Status: closed to accrual

This phase II trial studies how well APX005M works when given together with standard of care doxorubicin in treating patients with soft tissue sarcoma that has spread to other places in the body (advanced). Immunotherapy with APX005M, may induce changes in the body’s immune system, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving APX005M and doxorubicin may work better in treating patients with soft tissue sarcoma.